Modern Rheumatology最新文献_第10页

Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4. 日本类风湿关节炎患者服用非戈替尼的安全性和有效性：FINCH 4第156周中期结果。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2025-04-08 DOI: 10.1093/mr/roae099

Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Naoki Ishiguro, Shintaro Hirata, Kunihiro Yamaoka, Bernard G Combe, Peter Nash, Mark Genovese, Alena Pechonkina, Jie Liu, Akira Kondo, Haruhiko Fukada, Francesco De Leonardis, Tsutomu Takeuchi

{"title":"Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4.","authors":"Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Naoki Ishiguro, Shintaro Hirata, Kunihiro Yamaoka, Bernard G Combe, Peter Nash, Mark Genovese, Alena Pechonkina, Jie Liu, Akira Kondo, Haruhiko Fukada, Francesco De Leonardis, Tsutomu Takeuchi","doi":"10.1093/mr/roae099","DOIUrl":"10.1093/mr/roae099","url":null,"abstract":"Objectives: The aim of this article is to describe the safety and efficacy of filgotinib 200 mg (FIL200) or FIL 100 mg (FIL100) in Japanese patients with rheumatoid arthritis in a long-term extension (NCT03025308).Methods: Patients who completed any of three parent studies (NCT02889796: inadequate response to methotrexate; NCT02873936: inadequate response to biologic disease-modifying antirheumatic drugs; NCT02886728: methotrexate-naïve) without rescue therapy could enter the long-term extension; patients taking FIL continued their dosage, and those who received comparators were rerandomised to FIL200 or FIL100. This analysis includes Week 156 interim results.Results: Among Japanese patients, 110 received FIL200, and 97 received FIL100. Mean (SD) FIL200 and FIL100 exposure was 157.0 (51.49) and 156.0 (52.45) weeks. The exposure-adjusted incidence rates (95% confidence interval) for FIL200/FIL100 were 2.7 (1.4, 5.2)/2.4 (1.2, 5.1) for herpes zoster, 0.9 (0.3, 2.8)/1.0 (0.3, 3.2) for malignancy (excluding nonmelanoma skin cancer), and 0.6 (0.2, 2.4)/0.3 (0.0, 2.4) for major adverse cardiovascular events. More patients receiving FIL200 with prior FIL200 exposure achieved clinical remission vs other groups (including Clinical Disease Activity Index remission in 40% vs ≤27% at Week 156).Conclusions: FIL200 and FIL100 were generally well tolerated by Japanese patients, without new, unexpected adverse events.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"425-433"},"PeriodicalIF":1.8,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of orthopaedic surgical intervention on difficult-to-treat rheumatoid arthritis: A propensity score-matched study. 骨科手术干预对难以治疗的类风湿关节炎的影响：倾向得分匹配研究

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2025-04-08 DOI: 10.1093/mr/roae097

Shogo Toyama, Hajime Ishikawa, Asami Abe, Nariaki Hao, Hiroshi Otani, Sayuri Takamura, Masanori Sudo, Satoshi Ito, Kiyoshi Nakazono, Ryo Oda, Kenji Takahashi, Akira Murasawa

{"title":"Impact of orthopaedic surgical intervention on difficult-to-treat rheumatoid arthritis: A propensity score-matched study.","authors":"Shogo Toyama, Hajime Ishikawa, Asami Abe, Nariaki Hao, Hiroshi Otani, Sayuri Takamura, Masanori Sudo, Satoshi Ito, Kiyoshi Nakazono, Ryo Oda, Kenji Takahashi, Akira Murasawa","doi":"10.1093/mr/roae097","DOIUrl":"10.1093/mr/roae097","url":null,"abstract":"Objective:: To elucidate the therapeutic effect of orthopaedic surgical intervention (OSI) in difficult-to-treat rheumatoid arthritis (D2T RA) compared with non-D2T RA.Methods: A total of 534 recent surgeries were analysed only in patients who had undergone OSI since 2016 and for whom a 12-month postoperative follow-up was available. D2T RA was determined according to the European League against Rheumatism definition, and patients with D2T RA were matched to patients with non-D2T RA using propensity scores calculated by a logistic regression analysis. The Health Assessment Questionnaire-Disability Index (HAQ-DI), Disease Activity Index 28 (DAS28), face scale, and patient's assessment of general health were measured repeatedly at baseline and 6 and 12 months and were compared using a two-way analysis of variance.Results: The HAQ-DI, DAS28, face scale, and general health showed significant postoperative improvements, and there were significant differences in the HAQ-DI and face scale scores between D2T RA and non-D2T RA. An additional analysis with DAS28 as a covariate showed no significant interaction for either, suggesting that these improvements in clinical assessment were due to OSI rather than improved disease activity.Conclusions: In the absence of an effective pharmacological treatment strategy, OSI may be an effective treatment modality for the management of D2T RA.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"434-442"},"PeriodicalIF":1.8,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glucocorticoid tapering pace in microscopic polyangiitis and granulomatosis with polyangiitis in Japanese real-world practice: A propensity score-matched retrospective cohort study from the J-CANVAS registry. 在日本现实世界的实践中，显微镜下多血管炎和肉芽肿病伴多血管炎的糖皮质激素逐渐减少的速度：来自J-CANVAS注册的倾向评分匹配的回顾性队列研究。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2025-04-08 DOI: 10.1093/mr/roae112

Ryo Nishioka, Satoshi Omura, Daiki Nakagomi, Yoshiyuki Abe, Masatoshi Kadoya, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Naoya Kondo, Yasuhiko Yamano, Takuya Yanagida, Koji Endo, Shintaro Hirata, Kiyoshi Matsui, Tohru Takeuchi, Kunihiro Ichinose, Masaru Kato, Ryo Yanai, Yusuke Matsuo, Yasuhiro Shimojima, Ryota Okazaki, Tomoaki Takata, Takafumi Ito, Mayuko Moriyama, Ayuko Takatani, Yoshia Miyawaki, Toshiko Ito-Ihara, Takashi Kawaguchi, Nobuyuki Yajima, Takashi Kida, Yutaka Kawahito, Ichiro Mizushima

{"title":"Glucocorticoid tapering pace in microscopic polyangiitis and granulomatosis with polyangiitis in Japanese real-world practice: A propensity score-matched retrospective cohort study from the J-CANVAS registry.","authors":"Ryo Nishioka, Satoshi Omura, Daiki Nakagomi, Yoshiyuki Abe, Masatoshi Kadoya, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Naoya Kondo, Yasuhiko Yamano, Takuya Yanagida, Koji Endo, Shintaro Hirata, Kiyoshi Matsui, Tohru Takeuchi, Kunihiro Ichinose, Masaru Kato, Ryo Yanai, Yusuke Matsuo, Yasuhiro Shimojima, Ryota Okazaki, Tomoaki Takata, Takafumi Ito, Mayuko Moriyama, Ayuko Takatani, Yoshia Miyawaki, Toshiko Ito-Ihara, Takashi Kawaguchi, Nobuyuki Yajima, Takashi Kida, Yutaka Kawahito, Ichiro Mizushima","doi":"10.1093/mr/roae112","DOIUrl":"10.1093/mr/roae112","url":null,"abstract":"Objective: To assess the prevalence and outcomes among regimens of glucocorticoid tapering for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) in real-world practice.Methods: We retrospectively examined the Japan Collaborative Registry of Antineutrophil Cytoplasmic Antibodies-associated Vasculitis (J-CANVAS) registry, and evaluated the prevalence of glucocorticoid tapering regimens in the PEXIVAS trial. In patients with newly diagnosed MPA and GPA, we compared outcomes among standard and reduced pace regimens. Relapse-free survival rates were compared after propensity score matching.Results: Of 364 eligible patients, 113 (31.0%) received standard tapering and 251 slower tapering. After matching, 87 pairs no significant difference was observed in relapse-free survival (P = .506). Regarding the reduced regimen, there were so few patients (14/364, 3.8%) that statistical analysis was not performed.Conclusions: The glucocorticoid tapering for MPA and GPA in Japanese real-world practice was found to be generally slower than the standard regimen revealing a huge evidence-practice gap. Additionally, slower tapering did not improve relapse-free survival and might cause unnecessary glucocorticoid exposure.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"496-504"},"PeriodicalIF":1.8,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Validation of the 2022 ACR/EULAR classification criteria for giant cell arteritis in Korean patients with giant cell arteritis. Koran巨细胞动脉炎患者巨细胞动脉炎2022年ACR/EULAR分类标准的验证

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2025-04-08 DOI: 10.1093/mr/roae110

Jang Woo Ha, Jason Jungsik Song, Yong-Beom Park, Sang-Won Lee

{"title":"Validation of the 2022 ACR/EULAR classification criteria for giant cell arteritis in Korean patients with giant cell arteritis.","authors":"Jang Woo Ha, Jason Jungsik Song, Yong-Beom Park, Sang-Won Lee","doi":"10.1093/mr/roae110","DOIUrl":"10.1093/mr/roae110","url":null,"abstract":"Objectives: We applied the 2022 American College of Rheumatology (ACR)/European Alliance of Association for Rheumatology (EULAR) criteria to Korean patients previously diagnosed with giant cell arteritis (GCA) according to the 1990 ACR criteria and validated its clinical efficiency.Methods: Nine patients with GCA were included. The proportion of patients meeting each item of the 1990 ACR criteria and the 2022 ACR/EULAR criteria were assessed.Results: The median age was 65.0 years, and 77.8% of the patients were women. Seven (77.8%) patients had polymyalgia rheumatica. All nine patients were reclassified as having GCA according to the 2022 ACR/EULAR criteria. Among the 10 items of the 2022 ACR/EULAR criteria, the item contributing the most to the reclassification was elevated acute-phase reactant levels (100%), followed by new temporal headache (77.8%) and fluorodeoxyglucose positron emission tomography activity throughout the aorta (77.5%).Conclusions: In this study, for the first time, we demonstrated a concordance rate of 100% between the two criteria in Korean patients previously diagnosed with GCA. Moreover, we also clarified the major contributors to the reclassification according to the 2022 ACR/EULAR criteria.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"524-528"},"PeriodicalIF":1.8,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142951781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mortality and associated factors in patients with systemic sclerosis-associated pulmonary hypertension with and without interstitial lung disease: A long-term follow-up study. 伴有或不伴有间质性肺病的系统性硬化症相关肺动脉高压患者的死亡率及相关因素：长期随访研究

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2025-04-08 DOI: 10.1093/mr/roae095

Shirkhan Amikishiyev, Yasemin Yalçınkaya, Konul Mammadova, Numune Aliyeva, Gorkem Durak, Bahar Artim-Esen, Ahmet Gül, Ahmet Kaya Bilge, Gulfer Okumuş, Murat Inanc

{"title":"Mortality and associated factors in patients with systemic sclerosis-associated pulmonary hypertension with and without interstitial lung disease: A long-term follow-up study.","authors":"Shirkhan Amikishiyev, Yasemin Yalçınkaya, Konul Mammadova, Numune Aliyeva, Gorkem Durak, Bahar Artim-Esen, Ahmet Gül, Ahmet Kaya Bilge, Gulfer Okumuş, Murat Inanc","doi":"10.1093/mr/roae095","DOIUrl":"10.1093/mr/roae095","url":null,"abstract":"Objectives: We aimed to investigate mortality and prognostic factors in systemic sclerosis (SSc) patients with pulmonary hypertension (PH) with or without interstitial lung disease (ILD).Methods: The associations between mortality and demographics, transthoracic echocardiography, right heart catheterization (RHC), pulmonary functional parameters at baseline, and treatment modalities were evaluated.Results: Survival rates for PH-SSc patients (42 female, mean age 56.6 ± 13.5, median follow-up 45 months) were 91% at the first year, 75% at 2 years, and 43.1% at 5 years. The majority of the deceased patients had PH + ILD (P = .007). The PH + ILD group had more diffuse skin involvement, anti-Scl-70, high C-reactive protein, low FVC, and lower DLCO. The deceased patients had higher estimated pulmonary arterial systolic pressure (PASP), low cardiac output, and FVC values. Median survival time was significantly better in patients on combined therapy. Mortality-related factors in the PH + ILD group were decreased initial FVC, high estimated PASP, low cardiac output, deteriorated functional class, and monotherapy.Conclusion: This is the first reported SSc-PH cohort from Turkey by a multidisciplinary team. PH is a severe complication of SSc with high mortality especially in patients with accompanying severe ILD.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"478-483"},"PeriodicalIF":1.8,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142470024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The knowledge and skills required for the onco-rheumatologist: Study of four-year consultation records of a high-volume cancer centre. 肿瘤风湿病学家所需的知识和技能：对一家高容量癌症中心四年咨询记录的研究。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2025-04-08 DOI: 10.1093/mr/roae114

Koichi Takeda, Taro Shiga

{"title":"The knowledge and skills required for the onco-rheumatologist: Study of four-year consultation records of a high-volume cancer centre.","authors":"Koichi Takeda, Taro Shiga","doi":"10.1093/mr/roae114","DOIUrl":"10.1093/mr/roae114","url":null,"abstract":"Objectives: Onco-rheumatology, the intersection of oncology and rheumatology, is an emerging field requiring further definition. This study aimed to identify the knowledge and skills essential for rheumatologists in clinical oncology.Methods: We retrospectively reviewed consultations with the onco-rheumatology department of a high-volume tertiary cancer centre in Japan from January 2020 to December 2023.Results: We analysed 417 consultations. The most common consultation (229, 55%) was related to immune checkpoint inhibitor-induced immune-related adverse events (irAEs). Of the 238 irAEs in 185 patients, 15% were rheumatic and 85% were nonrheumatic (e.g. hepatobiliary toxicities, colitis). Approximately 25% of nonendocrine irAEs were refractory/relapsing, requiring second-line therapy (e.g. mycophenolate mofetil, biologics, immunoglobulin). In addition to irAE consultations, 137 (33%) consultations were about possible rheumatic diseases. The final diagnosis often related to cancer treatment, such as granulocyte colony-stimulating factor-related aortitis (15 patients, 11%), olaparib-related erythema nodosum (10 patients, 7.3%), and surgical menopause-related arthralgia (10 patients, 7.3%). Five patients (3.6%) were diagnosed with autoinflammatory bone disease mimicking bone tumours.Conclusions: Onco-rheumatologists are expected to play a central role in the management of a wide range of irAEs, not limited to rheumatic irAEs. They must also manage rheumatologic manifestations during cancer treatment and rheumatic diseases that mimic tumours.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"402-409"},"PeriodicalIF":1.8,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Laboratory markers predicting tofacitinib efficacy in Japanese patients with rheumatoid arthritis: A pooled analysis of Phase 2/3 randomised controlled clinical trials. 预测托法替尼对日本类风湿性关节炎患者疗效的实验室标记物：2/3期随机对照临床试验的汇总分析

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2025-04-08 DOI: 10.1093/mr/roae109

Yoshiya Tanaka, Hisashi Yamanaka, Shigeyuki Toyoizumi, Tomohiro Hirose, Tsutomu Takeuchi

{"title":"Laboratory markers predicting tofacitinib efficacy in Japanese patients with rheumatoid arthritis: A pooled analysis of Phase 2/3 randomised controlled clinical trials.","authors":"Yoshiya Tanaka, Hisashi Yamanaka, Shigeyuki Toyoizumi, Tomohiro Hirose, Tsutomu Takeuchi","doi":"10.1093/mr/roae109","DOIUrl":"10.1093/mr/roae109","url":null,"abstract":"Objectives: We characterised early changes in laboratory parameters in Japanese patients with rheumatoid arthritis and assessed whether these changes at Month (M)1 were predictive of tofacitinib efficacy at M3.Methods: This post hoc analysis included pooled data from Japanese patients receiving tofacitinib or placebo in three Phase 2/Phase 3 studies (NCT00603512; NCT00687193; NCT00847613). Outcomes included changes from baseline in laboratory parameters (Week 2 and M1/3); efficacy end points were Disease Activity Score in 28 joints, based on C-reactive protein; Disease Activity Score in 28 joints, based on erythrocyte sedimentation rate; and American College of Rheumatology-N index at M3. Univariate/multivariable analyses assessed whether changes at M1 were predictive of efficacy at M3.Results: Overall, 467 patients receiving tofacitinib and 104 receiving placebo were included. Tofacitinib treatment was associated with decreases from baseline in C-reactive protein, erythrocyte sedimentation rate, neutrophils, and platelets and increases in lymphocytes, haemoglobin, and lipids up to M3. Decreased platelet count and increased low-density lipoprotein cholesterol and haemoglobin at M1 were predictive of changes in efficacy outcomes at M3.Conclusions: Changes in laboratory parameters at M1 could potentially be used to assess whether tofacitinib therapy will be effective at M3; however, further investigation is needed.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"417-424"},"PeriodicalIF":1.8,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2025-04-08 DOI: 10.1093/mr/roae102

Riki Kurokawa, Sachiko Ohde, Satoshi Kawaai, Hiromichi Tamaki

{"title":"Factors related to acceptance of COVID-19 vaccine booster doses among patients with autoimmune and rheumatic diseases in Japan: A single-centre cross-sectional survey.","authors":"Riki Kurokawa, Sachiko Ohde, Satoshi Kawaai, Hiromichi Tamaki","doi":"10.1093/mr/roae102","DOIUrl":"10.1093/mr/roae102","url":null,"abstract":"Objectives: We studied the current state and factors associated with the acceptance or hesitancy of booster doses of the coronavirus disease 2019 (COVID-19) vaccine among patients with autoimmune and rheumatic diseases (ARDs) in Japan.Methods: A single-centre cross-sectional survey was conducted among outpatients with ARDs who visited the Immuno-Rheumatology Center at St. Luke's International Hospital from 1 October 2023 to 30 November 2023. We investigated patient characteristics, COVID-19 vaccination-related status, decision-making preferences, health-related status, and independent factors associated with the acceptance or hesitancy of booster doses of the COVID-19 vaccine.Results: A total of 241 patients were included in the analyses, and 198 patients (82.2%) received booster doses, while 43 (17.8%) did not. Older age [adjusted odds ratio (aOR) = 0.43, 95% confidence interval (CI): 0.19, 0.95, P = .037], having rheumatoid arthritis (aOR = 0.41, 95% CI: 0.19, 0.92, P = .030), and having a physician recommend receiving the vaccine (aOR = 0.47, 95% CI: 0.23, 0.95, P = .035) were independently associated with receiving booster doses. The main reasons for hesitancy regarding booster doses were concerns about adverse reactions and long-term safety.Conclusions: Our findings could help physicians counsel patients with ARDs regarding their acceptance of COVID-19 vaccine booster doses to promote appropriate decision-making.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"535-541"},"PeriodicalIF":1.8,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 study. anfrolumab治疗的日本系统性红斑狼疮患者的疾病活动性和糖皮质激素逐渐减少模式：TULIP-2研究中日本亚群的事后分析

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2025-04-08 DOI: 10.1093/mr/roae105

Yoshiya Tanaka, Tatsuya Atsumi, Masato Okada, Tomoya Miyamura, Tomonori Ishii, Susumu Nishiyama, Ryutaro Matsumura, Yosuke Morishima, Yoshiyuki Yamaguchi, Gabriel Abreu, Catharina Lindholm, Eric F Morand, Tsutomu Takeuchi

{"title":"Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 study.","authors":"Yoshiya Tanaka, Tatsuya Atsumi, Masato Okada, Tomoya Miyamura, Tomonori Ishii, Susumu Nishiyama, Ryutaro Matsumura, Yosuke Morishima, Yoshiyuki Yamaguchi, Gabriel Abreu, Catharina Lindholm, Eric F Morand, Tsutomu Takeuchi","doi":"10.1093/mr/roae105","DOIUrl":"10.1093/mr/roae105","url":null,"abstract":"Objectives: The aim of this study is to investigate the efficacy of anifrolumab in disease activity and glucocorticoid (GC) tapering patterns in Japanese patients with systemic lupus erythematosus (SLE).Methods: We analysed disease activity and GC tapering in the Japanese subpopulation (anifrolumab, n = 24; placebo, n = 19) of the Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP-2) trial, which showed the efficacy and safety of anifrolumab in patients with moderate-to-severe active SLE.Results: The percentage of patients who achieved a British Isles Lupus Assessment Group-based Composite Lupus Assessment response at Week 52 was greater in the anifrolumab group than in the placebo group [50.0% (12/24) vs 15.8% (3/19); P = .014]. Lupus low disease activity state (LLDAS) was achieved at Week 52 by 9/24 (37.5%) and 3/19 (15.8%) patients receiving anifrolumab and placebo, respectively. During the 52-week study period, in the anifrolumab vs placebo groups, 5/24 (20.8%) patients were in LLDAS ≥50% of the observed time vs 0/19 (0.0%), and 14/24 (58.3%) vs 6/19 (31.6%) patients were classified into favourable GC tapering patterns. Anifrolumab had an acceptable tolerability profile, consistent with the overall population.Conclusions: In the Japanese subpopulation of the TULIP-2 trial, anifrolumab resulted in improvements in disease activity to those reported for the overall population, suggesting a beneficial effect for disease control.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"470-477"},"PeriodicalIF":1.8,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The association between difficult-to-treat rheumatoid arthritis and probable sarcopenia. 难治性类风湿关节炎与可能的肌肉减少症之间的关系。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2025-04-08 DOI: 10.1093/mr/roae116

Yoshifumi Ohashi, Mochihito Suzuki, Yasumori Sobue, Kenya Terabe, Shuji Asai, Nobunori Takahashi, Shiro Imagama

{"title":"The association between difficult-to-treat rheumatoid arthritis and probable sarcopenia.","authors":"Yoshifumi Ohashi, Mochihito Suzuki, Yasumori Sobue, Kenya Terabe, Shuji Asai, Nobunori Takahashi, Shiro Imagama","doi":"10.1093/mr/roae116","DOIUrl":"10.1093/mr/roae116","url":null,"abstract":"Objectives: To identify factors associated with probable sarcopenia in patients with rheumatoid arthritis (RA).Methods: Probable sarcopenia was diagnosed using the SARC-F questionnaire. Patients with difficult-to-treat RA (D2T-RA) were defined as those with a history of using ≥2 biological/targeted synthetic (b/ts) disease-modifying antirheumatic drugs (b/tsDMARDs) who had moderate or high disease activity. Among 486 patients, 101 were classified into the probable sarcopenia group (SARC-F ≥4), and 385 were classified into the non-probable sarcopenia group (SARC-F <4). Factors associated with probable sarcopenia were examined using multiple logistic regression analysis. Additionally, patients were divided into the D2T-RA (n = 38) and non-D2T-RA (n = 448) groups, and the proportion of probable sarcopenia and RA treatment status were compared.Results: Factors associated with probable sarcopenia included age [adjusted odds ratio (OR): 1.03], body mass index (OR: 1.16), D2T-RA (OR: 3.39), and Health Assessment Questionnaire-Disability Index (OR: 1.38), and diabetes mellitus (OR: 2.77). The proportion of probable sarcopenia was significantly higher (60.5% vs. 17.4%), and the rate of methotrexate use was significantly lower (34.2% vs. 64.1%), in the D2T-RA group than in the non-D2T-RA group. Moreover, in the D2T-RA group, most patients used two or three b/tsDMARDs (two: 68.4%, three: 21.1%).Conclusions: D2T-RA was associated with probable sarcopenia. Tight control by treatment enhancement may help overcome sarcopenia.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"410-416"},"PeriodicalIF":1.8,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142951780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0